B cell-derived anti-beta 2 glycoprotein I antibody contributes to hyperhomocysteinemia-aggravated abdominal aortic aneurysm.
Overactivated B cells secrete pathological antibodies, which in turn accelerate the formation of abdominal aortic aneurysms (AAAs). Hyperhomocysteinemia (HHcy) aggravates AAA in mice; however, the underlying mechanisms remain largely elusive. In this study, we further investigated whether homocysteine (Hcy)-activated B cells produce antigen-specific antibodies that ultimately contribute to AAA formation. ELISA assays showed that HHcy induced the secretion of anti-beta 2 glycoprotein I (anti-β2GPI) antibody from B cells both in vitro and in vivo. Mechanistically, Hcy increased the accumulation of various lipid metabolites in B cells tested by LC-MS/MS, which contributed to elevated anti-β2GPI IgG secretion. By using the Toll-like receptor 4 (TLR4)-specific inhibitor TAK-242 or TLR4-deficient macrophages, we found that culture supernatants from Hcy-activated B cells and HHcy plasma IgG polarized inflammatory macrophages in a TLR4-dependent manner. In addition, HHcy markedly increased the incidence of elastase- and CaPO4-induced AAA in male BALB/c mice, which was prevented in μMT mice. To further determine the importance of IgG in HHcy-aggravated AAA formation, we purified plasma IgG from HHcy or control mice and then transferred the IgG into μMT mice, which were subsequently subjected to elastase- or CaPO4-induced AAA. Compared with μMT mice that received plasma IgG from control mice, μMT mice that received HHcy plasma IgG developed significantly exacerbated elastase- or CaPO4-induced AAA accompanied by increased elastin degradation, MMP2/9 expression, and anti-β2GPI IgG deposition in vascular lesions, as shown by immunofluorescence histochemical staining. Our findings reveal a novel mechanism by which Hcy-induced B cell-derived pathogenic anti-β2GPI IgG might, at least in part, contribute to HHcy-aggravated chronic vascular inflammation and AAA formation. HHcy is an independent risk factor for cardiovascular diseases in which B cell secretion of IgG antibodies play a key role. However, whether the antigen specific antibody production is changed during HHcy-accelerated AAA remains unclear. Our results provided the first evidence supporting the important role of activated B cell-derived anti-β2GPI IgG in HHcy-aggravated chronic vascular inflammation and AAA formation. It sheds new light on understanding pathogenesis of HHcy-accelerated AAA. In addition, anti-β2GPI IgG may be a potential diagnostic marker and therapeutic target for HHcy-related vascular injury.